Back to search

France· FR:64851088

EXTAVIA 250 microgrammes/mL, poudre et solvant pour solution injectable

A interferon beta-1b product containing interféron bêta-1b, registered in France by NOVARTIS EUROPHARM (IRLANDE). The same ATC class is registered in 14 of our 19 countries.

ATC L03AB08

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedEXTAVIA 250 microgrammes/mL, poudre e…ATCL03AB08REGISTER NO.FR:64851088PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Interferon beta-1b is registered in 14 of 19 countries.

Countries holding a registration under ATC L03AB08 (interferon beta-1b), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose

Interferon beta-1b · ATC L03AB08

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
INTERFÉRON BÊTA-1B
Manufacturer
NOVARTIS EUROPHARM (IRLANDE)
Country
France (FR)
ATC code
L03AB08
ATC class
Interferon beta-1b
Defined daily dose
4 MIO, E
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400926994358
    15 flacon(s) en verre - 15 seringue(s) préremplie(s) en verre de 1,2 ml dans 2,25 ml

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

347 interactions on record for interferon beta-1b.

Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Interferon beta-1b · interactions on record

347 records

  • 15 severe
  • 332 moderate

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • ZidovudineJ05AF01severe
  • ClotrimazoleA01AB18moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Interferon beta-1b in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All interferon beta-1b products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Betaferon
  • Liechtenstein · Betaferon
  • Norway · Betaferon

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/cba2bf9c-3986-4274-8df4-54218caf227b
GET /v1/drugs/cba2bf9c-3986-4274-8df4-54218caf227b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "64851088",
  "date_amm": "2008-05-20",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/08/454",
  "substance": "INTERFÉRON BÊTA-1B",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation abrogée",
  "statut_bdm": "Warning disponibilité",
  "forme_pharmaceutique": "poudre et  solvant pour solution injectable",
  "voies_administration": "sous-cutanée",
  "etat_commercialisation": "Non commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about interferon beta-1b.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.